Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al - Emery, Paul; Vencovský, Jiří; Ghil, Jeehoon; Kang, Jung Won (Annals of the rheumatic diseases, 2016)
Keywords: Antirheumatic Agents; Etanercept; antirevmatika; Treatment; Receptors, Tumor Necrosis Factor; Immunoglobulin G; revmatoidní artritida; Arthritis, Rheumatoid; Disease Activity; imunoglobulin G; etanercept; biosimilární léčivé přípravky; Rheumatoid Arthritis; Biosimilar Pharmaceuticals; receptory TNF